David Stevens is the interim-CEO of Vibalogics. Mr. Stevens brings more than 20 years of broad international operations and commercial experience in the CRO and CDMO sectors. He was formerly the Senior Vice President and Head of AMRI’s Drug Product business unit where he had P&L responsibility for sales and operations. During his tenure, he led the division through a period of significant growth and capacity expansion. Before leading the division, Mr. Stevens held senior leadership roles at AMRI including Vice President, Sales & Marketing and General Manager of a sterile dosage form development and GMP manufacturing facility.
Prior to AMRI, Mr. Stevens held roles of increasing responsibility at Aptuit, including a long-term international assignment in Italy where he led Operational Excellence and Capacity Planning for a >400-employee R&D and clinical GMP facility. He started his career with Inveresk and Charles River Laboratories. In July 2022 Mr. Stevens became the interim-CEO of Vibalogics, and is leading operational integration of Vibalogics Boxborough, Massachusetts and Cuxhaven, Germany facilities along with the Watertown facility (Arranta Bio), a part of post acquisition integrations by Recipharm AB of the newly formed advanced and emerging therapies business unit.
Mr. Stevens holds an MBA in strategy, finance and marketing from the University of Edinburgh and an undergraduate degree in business from Edinburgh.